

REMARKS

Claims 1, 4-9, 11-12, 14, 16-17, 20, 23, 26, 28-29, 31 and 48 are pending. Claims 2-3, 10, 13, 15, 18-19, 21-22, 24-25, 27, 30, 32-47 and 49-57 were previously canceled without prejudice or disclaimer.

The Examiner required restriction, under 35 U.S.C. §§ 121, between Groups I to XI as these inventions or groups of inventions allegedly are distinct from each other. Office action, pages 2-3. The Examiner noted that the restricted process claims that depend from or otherwise include all the limitations of an allowed process claim will be rejoined, as a matter or right, in accordance with the provisions of MPEP § 821.04. Office action, pages 4-5.

In response, Applicants hereby elect Group I, claims 1 and 17, drawn to and isolated polypeptide (SEQ ID NO:1) and compositions containing said polypeptide.

The Examiner is invited to contact the undersigned by telephone if it is felt that a telephone interview would advance the prosecution of the present application.


If there are any fees due in connection with the filing of this response, please charge the fees to Deposit Account No. 19-0741. If a fee is required for an extension of time under 37 C.F.R. § 1.136 not accounted for above, such an extension is requested and the fee should be charged to our Deposit Account.

Respectfully submitted,

Date Aug 21, 2004
FOLEY & LARDNER LLP

Customer Number: 22428

Washington Harbour
3000 K Street, N.W., Suite 500
Washington, D.C. 20007-5143
Telephone: (202) 295-4024
Facsimile: (202) 672-5399

By 
Robert M. Norway
Attorney for Applicant
Registration No. 54,608